.webp)
Customize your experience
You decide what information you want to see on your Sanofi Campus
More about science
Choose a therapeutic area to find related scientific content
.webp)
Atopic Dermatitis
Cardiovascular Diseases
CNS
Diabetes
Gut Health
Infectious Diseases and Vaccines
Kidney Transplant
Otolaryngeal Disorders
Pediatric Disorders
Rare Diseases
Respiratory Disease
Thrombosis
Latest trends
Explore the most popular scientific content among Sanofi Campus users
Importance of Titration and TIR Profile of 2nd Gen Basal Insulins
ALLSTAR – Reusable Insulin Delivery Device
Individualized dosing of r-ATG in Allo-HSCT
Treatment Outcomes of Newly Diagnosed Epilepsy
.webp)
Newsletter: EPIHEALTH
Neonatal seizures—diagnostic options and treatment recommendations
Treatment algorithm for convulsive status epilepticus: By American Epilepsy Society guideline committee
PBSEs: The consequences of antiepileptic drugs
Hot topics in kidney transplantation by Dr. Dorry Segev – Paradigm 6: Combining kidney exchange and desensitization
Hot topics in kidney transplantation by Dr. Dorry Segev – Paradigm 5: Kidney exchange beyond incompatibilities
MediBYTES March 2023: Recent updates impacting the patient outcomes
Fix fasting first: Treating fasting hypoglycemia
Support for your patients
Discover the selection of support materials for patients from different therapeutic areas
Sanofi Diabetes Dialogues - Debunking the myths
Worried about the flu spike of H3N2 strain?
Fabry disease: Dr Arvind’s story
Ensure complete protection for your school entry kid with DTP & IPV booster
Doctor discussion guide for patients
A new way to see atopic dermatitis
DTP Booster Guide
Family Vaccine Record
How to diagnose MPS I Disease
How To Diagnose Gaucher Disease
How to diagnose Pompe Disease
How to diagnose Fabry Disease
Beyond Therapy
Connect with content beyond therapeutic science through Campus
Clinical Trials in India
Why HCPs Need to Meditate: Guide to Reduce Stress & Burnout
Mental models for handling difficult situations in clinical practice
Patient Awareness and Empowerment: Effective Strategy for Optimal Therapeutic Outcomes
How to Improve Patient Care and Outcome Through Patient Education
Running your first marathon
NABL and NABH accreditation in India: Process and benefits
Physicians’ burnout and its implications
Mobile devices in clinical settings
Digital Trends in Healthcare: A Foretaste of the New Era of Science through Telemedicine
Our Products
Allegra® Suspension
Allegra® Suspension (Fexofenadine Hydrochloride Suspension) is indicated for relief of symptoms associated with allergic rhinitis in children 2-11 years of age and uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years of age.
Allegra® Nasal
Allegra® Nasal is indicated for the treatment of symptoms of allergic rhinitis. The dosage for adults and adolescents 12 years and over is 110 mcg (two sprays in each nostril) once daily, and for children 2 to 11 years of age is 55 mcg (one spray in each nostril) once daily. Allegra® Nasal is not recommended for children under 2 years of age.
Allegra® Nasal Duo
Allegra® Nasal Duo (Fluticasone Furoate 27.5 mcg and Azelastine Hydrochloride I.P. 140 mcg) is indicated for the treatment of symptoms of allergic rhinitis. It is indicated for the management of symptoms of allergic rhinitis, once the need for an antihistamine and corticosteroid has been established. It is recommended for the treatment of persistent, moderate to severe symptoms in adults and adolescents above 12 years of age.
Amaryl® M
Amaryl® M is fixed dose combination tablets of Metformin Hydrochloride Prolonged Release & Glimepiride. Amaryl® M is indicated for the management of patients with type 2 diabetes mellitus when diet, exercise and single agent (Glimepiride or Metformin alone) do not result in adequate glycemic control.
Amaryl® MP
Amaryl® MP is fixed dose combination tablets of Metformin Hydrochloride Sustained Release, Glimepiride & Pioglitazone Hydrochloride. Amaryl® MP is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.
Amaryl® MV
Amaryl® MV is fixed dose combination tablets of Metformin Hydrochloride (SR), Glimepiride & Voglibose. Amaryl® MV is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.
Amaryl® and Semi-Amaryl®
Semi-Amaryl® / Amaryl® is Glimepiride tablets which is an oral antidiabetic agent of the sulphonylurea group. Glimepiride is indicated for non-insulin dependent (type II) diabetes mellitus, whenever blood glucose levels cannot be controlled adequately by diet, physical exercise and weight reduction alone. Glimepiride may be combined with other, non-betacytotropic, oral antidiabetics. Glimepiride may also be used together with insulin (see dosage and administration).
Cardace®
Cardace® is Ramipril Tablets IP. Cardace® is indicated for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmHg or diastolic blood pressure > 90mmHg (or on antihypertensive treatment); total cholesterol >5.2mmol/L; HDL cholesterol < 0.9mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease. Prevention of myocardial infarction, stroke or cardio-vascular death and reduction of need for revascularization procedures in patients with an increased cardiovascular risk such as manifest coronary heart disease, a history of stroke or a history of peripheral vascular disease. Treatment of patients who within the first few days after an acute myocardial infarction have demonstrated clinical signs of congestive heart failure. Treatment of hypertension and cardiac failure. Treatment of non-diabetic or diabetic overt glomerular or incipient nephropathy.
Cardace® H
Cardace® H is fixed dose combination of Ramipril & Hydrochlorothiazide Tablets IP. Cardace® H is indicated for the treatment of mild to moderate hypertension in patients (in whom combination therapy is appropriate) who have been stabilized on the individual components given in the same proportion.
Cardace® Protect
Cardace® Protect is fixed dose combination of Ramipril & Atorvastatin Tablets. Cardace® Protect is indicated for treatment of patients with both essential hypertension and hypercholesterolemia. Ramipril has been found to reduce risk of MI, stroke or cardiovascular death in patients with increased risk. Atorvastatin has been found to reduce the risk of MI, stroke, revascularization procedures and angina in patients with CHD.
Stilnoct®
Stilnoct® contains zolpidem tartrate, a gamma-aminobutyric acid (GABA) A agonist of the imidazopyridine class. STILNOCT® (Zolpidem tartrate prolonged release tablets IP) is available in 6.25 mg and 12.5 mg strength tablets for oral administration. It is indicated for the short-term treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Synvisc-One™
Hylan® G-F 20 (Synvisc-One™) is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and to simple analgesics and for the treatment to decrease pain and discomfort allowing more extensive movement of the knee.
Tetraxim®
Tetraxim® vaccine is indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis: for primary vaccination in infants from the age of 2 months, for booster vaccination, one year after primary vaccination during the second year of life, and for booster vaccination between 5 and 13 years of age, according to official recommendations.
Valparin®
VALPARIN® (Valproate + Valproic Acid) is indicated for the treatment of generalized or partial epilepsy particularly with the following patterns of seizures: absence, myoclonic, tonic-clonic, atonic, mixed, as well as for partial epilepsy and manic episodes associated with bipolar disorder.
Vinlep™
VINLEP™ (oxcarbazepine) is indicated as Monotherapy and adjunctive therapy in the treatment of partial seizures (which include seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures) in adult patients. Treatment of generalized tonic-clonic seizures in adults and children. Adjunctive therapy in the treatment of partial seizures in children aged 4 -16 years. Monotherapy in the treatment of partial seizures in children aged 4-16 years.
Vinlep™ Suspension
Vinlep™ Suspension (Oxcarbazepine) is indicated in adults and children aged 1 month and above for the treatment of :
- Partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures)
- Generalized tonic-clonic seizures
Disclaimer: The images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.
This website is intended exclusively for Registered Medical Practitioners in India.
Please select the tab below to continue.